Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do We Need to Monitor B-Vitamins and Homocysteine During Initiation of Foslevodopa/Foscarbidopa Therapy?

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps.

Movement disorders clinical practice·2025
Same author

Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q-Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study.

European journal of neurology·2025
Same author

Dysphagia in Multiple System Atrophy Does Not Correlate with Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

Thalamic Deep Brain Stimulation for Dystonic Head Tremor: A Long-Term Study of 18 Patients.

Movement disorders clinical practice·2025
Same author

Validation of clinical ratings of cervical dystonia using computer-generated avatars.

Parkinsonism & related disorders·2025
Same journal

Key Interventions in Friedreich's Ataxia and Their Impact on Patient Outcomes: A Systematic Review.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Reply to Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

Intertemporal choice in Parkinson's disease.

Maria Milenkova1, Bahram Mohammadi, Katja Kollewe

  • 1Department of Neurology, Medical School Hannover, Hannover, Germany.

Movement Disorders : Official Journal of the Movement Disorder Society
|May 14, 2011
PubMed
Summary
This summary is machine-generated.

Parkinson's disease patients exhibit impulsive decision-making, showing steeper discounting of future rewards compared to healthy individuals. This impulsivity persists regardless of dopamine agonist medication status.

More Related Videos

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Experiment Videos

Last Updated: Jun 2, 2026

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
09:12

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats

Published on: March 17, 2019

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Area of Science:

  • Neuroscience
  • Behavioral Economics
  • Clinical Neurology

Background:

  • Dopamine agonists used in Parkinson's disease treatment are linked to impulse control disorders.
  • Understanding decision-making deficits in Parkinson's disease is crucial for patient care.

Purpose of the Study:

  • To investigate intertemporal monetary choice behavior in Parkinson's disease patients without diagnosed impulse control disorders.
  • To compare decision-making patterns between patients on and off dopamine agonist medication versus healthy controls.

Main Methods:

  • 17 Parkinson's disease patients and 17 matched controls chose between immediate and delayed monetary rewards.
  • Hyperbolic discounting model used to estimate 'k' values representing impulsivity.
  • Patients were tested twice: on medication and after 12 hours off medication.

Main Results:

  • Parkinson's disease patients demonstrated significantly steeper discounting (k values >3x higher) than controls.
  • This steeper discounting was observed irrespective of medication status.
  • No significant difference in discounting was found between on- and off-medication testing sessions for patients.

Conclusions:

  • Parkinson's disease patients, even without overt impulse control disorders, tend to make more impulsive choices.
  • The medication-independent nature of this impulsivity suggests potential underlying neurological changes.
  • The study highlights the utility of intertemporal choice paradigms for assessing decision-making in Parkinson's disease.